India tightens drug safety rules after deadly cough syrup scandal

India’s drug regulator has tightened rules on monitoring medicine safety. The Central Drugs Standard Control Organisation (CDSCO) issued a new circular to pharmaceutical companies, stressing the need for stronger pharmacovigilance systems. This follows concerns over contaminated cough syrups linked to child deaths abroad and wider worries about drug quality control. The CDSCO’s latest directive reminds manufacturers of their duty to track and report adverse drug reactions. Under Schedule M—India’s Good Manufacturing Practices (GMP) guidelines—firms must already maintain systems for detecting and recording side effects. Recent updates to these rules have brought Indian standards closer to global benchmarks set by the World Health Organization (WHO).

Regulatory officers from the CDSCO, State Licensing Authorities, and Union Territory administrations will now check compliance during routine inspections. A well-functioning pharmacovigilance system allows regulators to spot safety risks early, pull unsafe products from shelves, and avoid large-scale health emergencies. The move comes after contaminated cough syrups made in India were linked to child fatalities overseas. Authorities have since focused on improving post-marketing surveillance to prevent similar incidents in the future.

The new measures require drugmakers to strengthen their monitoring of adverse reactions. Inspections will verify whether companies follow the updated pharmacovigilance rules. Early detection of safety issues could help avoid public health crises and improve trust in Indian pharmaceuticals.